secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0000950170-25-026063
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics reports Q4 2024 net loss $16.6M; cash $241M, runway into at least 2027
--------------------------------------------------------------------------------

- Full-year 2024 net loss $9.7M vs $97.3M in 2023, driven by $80M Sanofi upfront payment.
- Cash and marketable securities $241.0M as of Dec 31, 2024, sufficient into at least 2027.
- Phase 1b PIONEER trial of pociredir in SCD: 10 patients enrolled in 12 mg cohort; data expected mid-2025.
- Plan to submit IND for Diamond-Blackfan anemia program in Q4 2025.
- Phase 3 REACH trial (losmapimod) data to be presented at MDA Conference on March 19, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000095017025026063/0000950170-25-026063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000095017025026063/fulc-20250225.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-026063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer